A Turning Point For Gene Therapy: What One Tragic Event Reveals About The Promise And Peril Of Genetic Medicine
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Yahoo
Pfizer says patient dies after receiving hemophilia drug in trial
FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...
Seeking Alpha
Intellia plunges as Q3 updates indicate patient death in gene editing trial
Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who experienced a liver-related adverse event in a Phase 3 trial for its nex-z ...
FiercePharma
FDA restricts Sarepta's gene therapy Elevidys after Duchenne patient deaths
The FDA has officially limited the label of Sarepta Therapeutics’ Elevidys, putting an end to a whirlwind few months that saw the abrupt departure—and reinstatement—of top agency official Vinay Prasad ...
Medscape
Gene Therapy Shows Lipid Improvement but Raises Flags
NEW ORLEANS — New data from a first-in-human trial of a CRISPR-based gene therapy for cholesterol disorders are giving lipids experts reason for optimism about the approach for treating cardiovascular ...
MedPage Today on MSN
CAR7 Gene Therapy Shows Promise in T-Cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
The Boston Globe
Intellia tumbles after patient dies following Crispr treatment
Intellia Therapeutics Inc. shares dropped after the company said a patient died after suffering liver damage in a clinical trial for the company’s gene-editing treatment. The patient, who was in his ...